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Background: Sudden unexpected death in epilepsy (SUDEP) is a major cause of death
in those with drug-resistant epilepsy (DRE). There is a need for inventories and biomarkers
associated with the risk for SUDEP.
Objective: To explore the revised SUDEP Risk Inventory (SUDEP-7) in a cohort with DRE
and determine the association with Heart Rate and other covariates.
Methods: Twenty-five subjects with severe DRE were enrolled in a clinical trial for
epilepsy. Baseline demographics, duration of epilepsy, seizure types, seizure frequency,
seizure severity, AEDs, and vital signs were collected. Heart rate variability (HRV) was
calculated from 1-h recordings of ECG. A SUDEP Risk Inventory (SUDEP-7) was
administered, which included seven validated and weighted risk factors initially identified
by Walczak et al. as factors associated with SUDEP risk.
Results: The total score on the revised SUDEP-7 ranged from 1 to 7, mean=3.4 (SD
1.8). The SUDEP Risk Inventory score was inversely correlated with RMSSD (Pearson
r= 0.45, p=0.027). The following variables were significantly associated with RMSSD:
epilepsy duration (p=0.02), age (p=0.03), and developmental intellectual disability
(p<0.001). The correlation between RMSSD and SUDEP-7 tended to persist also after
the adjustment for patient age (r= 0.40, p=0.05). Two subjects died of SUDEP: their
SUDEP-7 scores were above average and in the upper twenty-fifth and fiftieth percentiles,
respectively (6 and 4, mean=3.4).
Conclusion: RMSSD, a measure of low frequency HRV, was significantly associated
with SUDEP Risk Inventory (SUDEP-7) scores. Using a multivariate model, the covariates
of developmental intellectual disability, age, and duration of epilepsy were also signif-
icantly associated with decreased HRV. The correlation between decreased HRV and
a higher SUDEP-7 score remained unchanged even after the adjustment for patient
age. The results suggest that older age, greater duration of epilepsy, and the presence
of developmental intellectual disability may increase the risk of SUDEP through their
direct influence on decreasing the vagus nerve-mediated HRV. Further validation of the
SUDEP-7 inventory is indicated.
Trial Registration: ClinicalTrials.gov, NCT00871377.
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INTRODUCTION
Sudden unexpected death in epilepsy (SUDEP) accounts for
16–36% of deaths in people with epilepsy and has an annual
incidence of three to nine per 1,000 in the general epilepsy popu-
lation (1). In drug-resistant epilepsy (DRE), the annual incidence
of SUDEP is about one in 150 (2). Clinical risk factors have
been prospectively identified in multiple studies. These risk fac-
tors include frequent generalized tonic–clonic seizures and long
duration of epilepsy among others (2, 3).
There is a critical need for biomarkers and a screening inven-
tory so patients at riskmay be identified prior to death. This would
create an opportunity to educate,monitor, and intervene to reduce
the risk of SUDEP. In 2011, our group reported the first SUDEP
Risk Inventory (SUDEP-7), which includes seven validated risk
factors for SUDEP (4). The SUDEP-7 has been associated with
two biomarkers of SUDEP risk: RMSSD and postictal generalized
EEG suppression (PGES) (4, 5). RMSSD, the root mean square
differences of successive R–R intervals, is a measure of vagus-
mediated heart rate variability (HRV) and autonomic regulation
of the heart. Low HRV, as measured by RMSSD, has been asso-
ciated with atrial fibrillation, cardiovascular disease, and poor
outcomes in patients with heart failure (6). In this report, we
evaluate a revised SUDEP-7 Risk Inventory in a complete cohort
of 25 patients with severe DRE.We correlate the revised SUDEP-7
with HRV, age, duration of epilepsy, and other key covariates and
evaluate the associations of HRV with the individual risk factors
of SUDEP-7 in bivariate fashion and in a multivariable model.
METHODS
Subjects were enrolled in a prospective double-blind crossover
trial of a study of fish oil for epilepsy (clinicaltrials.gov #
NCT00871377). Institutional Research Committee approval was
secured prior to initiating the study, and informed consent was
obtained from each subject or their guardian at enrollment. Inclu-
sion criteria were as follows: ages 18–70; a history of localized, par-
tial epilepsy; a history of generalizes tonic–clonic or tonic seizures
with loss of consciousness; DREwith three ormore simple partial,
complex partial, or tonic–clonic seizures per month (1981 ILAE
classification, partial onset seizures with or without loss of con-
sciousness); prior exposure to at least one or more antiepileptic
drugs at therapeutic doses alone or in combination; an EEG
and/or anMRI consistent with a localization related epilepsy; and
at least three seizures per month for at least 2months prior to
the study. Exclusion criteria were as follows: progressive medi-
cal, cardiac, or other illness; allergy to fish products or fish oil;
history of coagulation disorder; history of non-epileptic seizures;
consumption of fish oil 30 days or less prior to enrollment; any
change in antiepileptic drugs 30 days or less prior to enrollment;
warfarin treatment 30 days or less prior to enrollment; history of
poor compliancewith therapy; drug or alcohol abuse; uncountable
seizures as a result of seizure clustering; and pregnancy.
At entry, subjects underwent a history and a physical exam,
and their seizure calendars were reviewed and validated. A base-
line seizure frequency was calculated from the validated seizure
calendars. A National Hospital/Chalfont seizure severity scale
was administered, and a score was calculated at baseline. Vital
signs (heart rate, blood pressure, and weight) were determined
and recorded. Subjects underwent a 1-h electrocardiogram in the
resting, awake state in the sitting position, using a PhilipsDigitrak-
plus 24 digital Holter monitoring system with a frequency range
of 0.5–60Hz and a sampling rate of 175Hz (Philips Digitrak-Plus
24). Time-dependent measures of HRVwere calculated as defined
by Stein et al., and they included SDNN, SDANN, and RMSSD.
SDNN is defined as the mean of the SDs for all R–R intervals;
SDANN is defined as the SDs of all R–R intervals in successive
5-min epochs; and RMSSD is defined as the root mean square
difference of successive R–R intervals (7).
For this study, a revised SUDEP-7 Risk Inventory was adapted
from the original SUDEP-7 Risk Inventory. The SUDEP-7 Risk
Inventory (Version 2.0) includes seven risk factors validated by
Walczak et al. and weighted by multiplying the reported odds
ratios by the natural log (loge) (3). The revised SUDEPRisk Inven-
tory uses amodified scoringmethodology to prevent overinflating
subjects’ SUDEP score. Subjects with risk factor 1 (three or more
tonic–clonic seizures in the last year) scored a 0 for risk factor 2
(one tonic–clonic seizures in the last year). Similarly, subjects with
risk factor 4 (50 or more seizures per month) scored a 0 for risk
factor 3 (one seizure in the last year).
All subjects were assessed with the SUDEP-7 Risk Inventory
(SUDEP-7), and 24/25 completed HRV testing.
Statistical Analysis
We evaluated the relationship between SUDEP-7 versus RMSSD
using the Pearson correlation after confirming linearity. We
reported the summary statistics for RMSSD including the mean
(SD) and median by quartiles of the SUDEP-7 score and evaluate
the association of RMSSD versus the SUDEP-7 quartile using the
Spearman correlation (test of trend).
We compared the baseline RMSSD measure by level of each
individual risk factor of SUDEP-7 using the Wilcoxon rank sum
test or the t-test as appropriate. We evaluated the relationship
between RMSSD versus the subset of the most important risk
factors of SUDEP simultaneously using the non-parametric linear
regression model with bootstrapping.
To evaluate the relationship between SUDEP-7 versus RMSSD
while controlling for the covariates, such as age and sex, we used
the linear regression model after confirming the normality and
constant variance assumptions. Linearity was confirmed by fitting
splines.
RESULTS
Twenty-five subjects with severe DRE were enrolled. Mean age
was 33.0 years (SD 10.3), with 15 females and 10 males. Average
duration of epilepsy was 21.5 years (SD 11.2). Patients in this
cohort were highly drug resistant, with a mean seizure frequency
of 25.1 seizures per month (SD 59.4).
Table 1 summarizes the clinical data for the cohort. Table 1 is
divided into four quartiles depending on SUDEP-7 score. The total
score on the SUDEP-7 ranged from 1 to 7, mean= 3.4 (SD 1.8)
out of a maximum possible score of 10. Table 2 summarizes the
core components of the SUDEP-7 inventory, and the number of
subjects with each factor.
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TABLE 1 | Summary of data for the cohort of patients, stratified by SUDEP Risk Inventory score (SUDEP-7).
Quartile by
SUDEP-7 score
SUDEP-7
score
Age Sex Duration of
epilepsy (years)
Seizures
per month
RMSSD
(ms)
Mean RMSSD
by quartile
76–100% 7 45 M 45 6 14.9 17.6ms SD 5.1
6 21 M 16 60 22.3
6 18 F 17 24 N/A
5 46 F 31 3 21.4
5 28 F 28 20 11.8
51–75% 4 56 F 44 5 15.1 25.6ms SD 5.8
4 44 M 33 6 32.0
4 32 M 31 3 23.8
4 40 F 34 3 20.9
4 42 F 30 30 26.4
4 32 M 14 3 30.4
4 30 M 22 5 33.6
4 34 F 29 5 23.5
4 30 M 26 15 24.5
25–50% 3 28 F 20 8 60.3 35.8ms SD 17.2
3 19 M 5 60 26.5
3 37 M 15 300 21.3
2 32 F 10 10 23.3
2 22 F 12 4 47.5
0–25% 1 28 F 7 7 20.9 32.0ms SD 12.5
1 24 M 10 12 31.3
1 37 F 7 5 31.5
1 26 F 21 10 31.0
1 22 F 17 10 55.4
1 53 F 13 13 21.7
Mean 2.96 33.04 21.48 25.08 27.9 27.9
SD 1.59 10.3 11.20 59.35 11.8 11.8
The mean RMSSD decreased with each increasing quartile of SUDEP-7, p=0.032, trend test.
TABLE 2 | The SUDEP Risk Inventory (SUDEP-7, version 2.0) with each risk
factor, weighting, and scoring convention.
SUDEP Risk Inventory
(version 2.0)
Odds ratio Weighting
loge odds
ratio
Number of
subjects with
each risk factor
1. More than three tonic–
clonic seizures in last year
8.1 0 or 2 6
2. One or more tonic–clonic
seizures in last year (if factor 1
present, score as 0)
2.4 0 or 1 9
3. One or more seizures of any
type over the last 12months
(if factor 4 present, score as 0)
2.2, 3.8, 4.6 0 or 1 24
4. >50 seizures of any type per
month over the last 12months
11.5 0 or 2 3
5. Duration of epilepsy>30 years 13.9 0 or 3 7
6. Use of three or more AEDs 4.0 0 or 1 9
7. Developmental disability, I.Q.
<70 or too impaired to test
5.0 0 or 2 3
The SUDEP-7 score was inversely correlated with RMSSD,
one of the three core measures of HRV (Pearson r= 0.43, p-
value= 0.035, Figure 1). Subjects in the highest SUDEP-7 quar-
tile (scores= 5–7) had significantly lower RMSSD values than
FIGURE 1 | Plot of RMSSD versus SUDEP-7 score. The SUDEP-7 score
was inversely and significantly associated with heart rate variability (RMSSD),
r= 0.43, p-value= 0.0351.
subjects in the lowest SUDEP-7 quartile (scores= 1). The mean
RMSSD for the highest SUDEP-7 quartile was 17.6ms (SD= 5.1).
The mean RMSSD for the lowest SUDEP-7 quartile was 32.0ms
(SD= 12.5). RMSSD decreased significantly with each increas-
ing quartile of SUDEP-7, p= 0.032, trend test, see Table 1. The
SUDEP-7 score was also correlated with duration of epilepsy
(r= 0.69, p< 0.001, Pearson moment correlation, Figure 2).
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FIGURE 2 | Plot of epilepsy duration versus SUDEP-7 score. Epilepsy
duration was significantly associated with SUDEP-7 score, r= 0.69,
p<0.001.
Subjects with developmental intellectual disabilities (men-
tal retardation) had significantly lower baseline RMSSD values
compared to subjects without developmental intellectual dis-
abilities: mean RMSSD values for patients with developmental
intellectual disabilities were 16.3 versus 29.6ms in those with-
out developmental intellectual disabilities (p= 0.026, Wilcoxon
rank sum test). Age was inversely correlated with RMSSD
values, with lower RMSSD values in older subjects (r= 0.45,
p= 0.028). In addition, greater duration of epilepsy was cor-
related with decreased RMSSD (r= 0.65, p= 0.02, for persons
with >20 years duration). The covariate of epilepsy duration
(adjusted mean rate of change= 0.71ms/year, p= 0.008, for
patients with >20 years duration) remained significantly asso-
ciated with decreased RMSSD even when controlled for in the
same multivariable model. Older age tended to be associated
with greater SUDEP-7 score, although this association did not
reach statistical significance (r= 0.24, p= 0.25). The correlation
between decreased RMSSD and greater SUDEP-7 score trended
even after the adjustment for age (r= 0.40, p= 0.05), but any
effect of age on SUDEP-7 entirely disappeared once RMSSD was
accounted for in the multivariable model.
Two patients died from autopsy-confirmed SUDEP. One died
during the study, and one died after exiting the study. The SUDEP-
7 score for subject one was 4, and the SUDEP-7 score for subject
13 was 6. Table 3 summarizes the SUDEP-7 for the two subjects
who died of SUDEP. Note, both reported three or more GTC
seizures, and both were taking three or more AEDs. Subject 13
had a developmental intellectual disability (see Table 3).
DISCUSSION
We report the revised SUDEP-7 Risk Inventory in a cohort with
severe DRE. Scores in the top SUDEP-7 quartile ranged from
5 to 7. All scores in the lowest SUDEP-7 quartile were 1. Two
subjects (8%) died of SUDEP. One was in the highest quartile
(SUDEP-7 score= 7), and the other was in the second highest
quartile (SUDEP-7 score= 4). Both subjects had above-average
SUDEP-7 scores when compared with the mean score of 3.4. The
TABLE 3 | SUDEP-7 scores of two subjects who died of autopsy-confirmed
SUDEP.
SUDEP-7 Risk Inventory (SUDEP-7) Subject 1 Subject 13
1. More than three tonic–clonic seizures in last year 2 2
2. One or more tonic–clonic seizures in last year 0 0
3. One or more seizures of any type over the last
12months
1 1
4. >50 seizures of any type per month over the last
12months
0 0
5. Duration of epilepsy 30 years 0 0
6. Concurrent use of >3 antiepileptic drugs 1 1
7. Developmental intellectual disability, I.Q. <70, or
too impaired to test
0 2
Total score 4 6
high incidence of SUDEP is likely due to the high severity and
longstanding duration of epilepsy in this cohort.
The revised SUDEP-7 Risk Inventory was associated with
the biomarker RMSSD, a measure of vagus-mediated HRV.
High SUDEP-7 scores (SUDEP-7 scores of >5) were signifi-
cantly associated with low values of RMSSD. Low SUDEP-7
scores, indicating lower risk for SUDEP, were associated with
higher values of vagus-mediated HRV (RMSSD). Age, duration
of epilepsy, and developmental intellectual disability were all
associated with reduced vagus-mediated HRV (RMSSD). The
correlation of RMSSD and SUDEP-7 persisted even after the
adjustment for patient age, but any effect of age on SUDEP-7
completely disappeared once RMSSD was accounted for in the
multivariable model. The results suggest that older age, greater
duration of epilepsy, and presence of developmental disabilitymay
increase SUDEP risk through their direct influence on vagus nerve
mediated HRV (8).
This article adds to data from the initial cohort of 19 patients
published in 2010 and now includes the entire study cohort of 25
subjects, with stratification of SUDEP-7 scores into quartiles, and
needed modifications to the original methodology for calculating
the SUDEP-7 score. This study adds to evidence that patients
with developmental disability may have higher risk for SUDEP.
This expanded study also provides new evidence that patients
with SUDEP-7 scores in the highest quartile have significantly
greater autonomic dysfunction of the heart than patients with
low SUDEP-7 scores (6, 7, 9, 10). The values of RMSSD for
the highest SUDEP-7 quartile averaged 17.6ms and are similar
to values in patients with heart disease at high risk for heart
failure. In a recent study of 4,652 patients with cardiac risk fac-
tors who underwent HRV testing, subjects with RMSSD values
similar to those in the highest SUDEP-7 quartile had significantly
higher risk for heart failure. In that study, hazard ratios (HR)
for heart failure ranged from a HR of 4.7:1 for RMSSD values
<16 to 2.8:1 for RMSSD values of 16–26.9ms. This indicates
that patients at highest risk of SUDEP have autonomic dys-
function similar to that found in patients at high risk for heart
failure.
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The SUDEP-7 Risk Inventory now requires further validation
in larger populations. Moseley et al. have correlated the SUDEP-7
with another biomarker, PGES. PGES was found to occur fol-
lowing seizures in 32.4% of 37 children monitored in a pediatric
epilepsy unit (5). PGES was highly correlated with the SUDEP-
7 inventory (5). Children with PGES had significantly higher
SUDEP-7 scores than those without PGES SUDEP-7 score= 4.2
for those with PGES, versus 2.8 for those without PGES (5).
The strong association between the SUDEP-7 inventory with a
second biomarker is an important discovery and provides further
independent validation.
The question of whether to include the risk factor of three
or more ongoing AEDs is an ongoing question (8). Hesdorffer
et al. found that the number of AEDs was not an independent
predictor of SUDEP risk, after adjusting for the presence/absence
of generalized tonic–clonic seizures (GTCS), age at death, and
gender (11). The number of AEDs may simply reflect the severity
of epilepsy and not SUDEP risk. Walczak et al. did report that
three or more AEDs were an independent risk factor for SUDEP,
and both subjects who died of SUDEP scored positive for the risk
factor of greater than three AEDs. Further exploration regarding
inclusion of three or more AEDs as a risk factor is indicated.
In summary, we report the revised SUDEP-7 Risk Inventory
(SUDEP-7) in a cohort with severe DRE. The SUDEP-7 was
associated with a biomarker of vagus-mediated HRV. The highest
SUDEP-7 scores of 5–7 were associated with levels of autonomic
function found in patients at high risk for heart failure, which
reflects severely deranged autonomic control of the heart. We
believe further investigation of the SUDEP-7 Risk Inventory is
indicated.
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